Skip to main content

Advertisement

Table 5 Haplotype distributions of VEGF p olymorphisms in cases and controls and their association with the risk of developing endometriosis

From: Role of vascular endothelial growth factor polymorphisms (-2578C > A, -460 T > C, -1154G > A, +405G > C and +936C > T) in endometriosis: a case–control study with Brazilians

-2578C > A/ -460 T > C/ -1154G > A/ +405G > C VEGFhaplotypes Controls All Cases Pvalueb OR (95% CI)c DIE Cases Pvalueb OR (95% IC)d Stages III-IV Pvalueb OR (95% IC)e
(N = 112) (N = 182) (N = 151) (N = 110)
N (%)
N (%)
No (%) No (%)
CTGG 42 (18.7) 85 (23.4)   1a 69 (22.9)   1a 55 (25.0)   1a
CTGC 90 (40.1) 121 (33.2) 0.10 0.66 (0.42 – 1.05) 104 (34.4) 0.18 0.70 (0.44 – 1.13) 69 (31.3) 0.05 0.58 (0.35 – 0.97)
ACAG 36 (16.0) 96 (26.4) 0.38 1.32 (0.77 – 2.24) 78 (25.8) 0.40 1.32 (0.76 – 2.29) 58 (26.4) 0.58 1.23 (0.69 – 2.19)
ACGG 37 (16.5) 51 (14.0) 0.23 0.68 (0.39 – 1.19) 42 (13.9) 0.27 0.69 (0.38 – 1.24) 31 (14.1) 0.21 0.64 (0.34 – 1.19)
CCGG 15 (6.7) 11 (3.0) 0.03 0.36 (0.15 – 0.86) 9 (3.0) 0.05 0.37 (0.15 – 0.90) 7 (3.2) 0.05 0.35 (0.13 – 0.95)
ATGG 4 (2.0) 0 (0.0) 0.03 - 0 (0.0) 0.05 - 0 (0.0) 0.09 -
  1. OR is odds ratio, CI is confidence interval. aReference Group; bChi-Square Test or Fisher’s exact test; cControls vs. Cases (All patients with endometriosis); dControls vs. Deeply infiltrating endometriosis patients (DIE); eControls vs. Moderate or severe endometriosis patients (stages III or IV).